International Congress of Dermatology (ICD), 2025

Bimekizumab impact on draining tunnel and lesion count over 2 years in hidradenitis suppurativa: Data from BE HEARD EXT

Bimekizumab impact on efficacy and patient-reported outcomes in moderate versus severe hidradenitis suppurativa

Efficacy and safety of bimekizumab to 2 years in patients with psoriatic arthritis by baseline psoriasis severity

Bimekizumab cumulative health-related quality of life benefit by clinical response in patients with hidradenitis suppurativa: 1 year data from BE HEARD I&II

Bimekizumab 5-year maintenance of response in US and Canadian patients with psoriasis who responded at Week 16

Bimekizumab time to onset of PASI response in patients with psoriasis in three head-to-head phase 3/3b studies

Bimekizumab maintenance of response during treatment interruption and retreatment in US/Canadian patients with psoriasis

Bimekizumab 3-year efficacy in patients with psoriasis and risk factors for progression to psoriatic arthritis or screening positive for psoriatic arthritis: Long-term results from BE BRIGHT and BE RADIANT

Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials

Bimekizumab maintenance of efficacy over 4 years in biologic-naïve andbiologic-experienced patients with moderate to severe plaque psoriasis